Phosphorylation: new star of pathogenesis and treatment in steatotic liver disease

Abstract Steatotic liver disease poses a serious threat to human health and has emerged as one of the most significant burdens of chronic liver disease worldwide. Currently, the research mechanism is not clear, and there is no specific targeted drug for direct treatment. Phosphorylation is widely re...

Full description

Bibliographic Details
Published in:	Lipids in Health and Disease
Main Authors:	Tiansu Lv, Yan Lou, Qianhua Yan, Lijuan Nie, Zhe Cheng, Xiqiao Zhou
Format:	Article
Language:	English
Published:	BMC 2024-02-01
Subjects:	Phosphorylation Steatotic liver disease NAFLD Pathogenesis
Online Access:	https://doi.org/10.1186/s12944-024-02037-9

Similar Items

Pathogenesis of metabolic dysfunction-associated steatotic liver disease and donor liver damage
by: Chuheng Gou, et al.
Published: (2025-12-01)

An overview of pathogenesis of metabolic dysfunction-associated steatotic liver disease
by: Shahid Habib, et al.
Published: (2024-11-01)

Gene Variants Implicated in Steatotic Liver Disease: Opportunities for Diagnostics and Therapeutics
by: Gary Huang, et al.
Published: (2023-10-01)

Sex-specific associations of metabolic dysfunction-associated steatotic liver disease with cardiovascular outcomes
by: Meng-Yuan Miao, et al.
Published: (2025-01-01)

Metabolic associated steatotic liver disease misses fewer high-risk patients than metabolic associated fatty liver disease
by: Yu-Ming Cheng, et al.
Published: (2024-12-01)

Insulin resistance and central obesity determine hepatic steatosis and explain cardiovascular risk in steatotic liver disease
by: Georg Semmler, et al.
Published: (2023-09-01)

A new name for an old problem. Metabolic dysfunction-associated steatotic liver disease - review of literature
by: Adrian Kruszewski, et al.
Published: (2024-07-01)

Steatotic Liver Disease: Metabolic Dysfunction, Alcohol, or Both?
by: Katharina Staufer, et al.
Published: (2023-07-01)

New steatotic liver disease criteria diagnostic performance in an agricultural population in Chile
by: Maria Spencer-Sandino, et al.
Published: (2025-07-01)

Mechanisms and therapeutic targets of mitochondria in the progression of metabolic dysfunction-associated steatotic liver disease
by: Chenyang Mu, et al.
Published: (2025-01-01)

A new Korean nomenclature for steatotic liver disease
by: Nonalcoholic Fatty Liver Disease (NAFLD) Nomenclature Revision Consensus Task Force on behalf of the Korean Association for the Study of the Liver (KASL)
Published: (2024-09-01)

Evaluation of Liver Fibrosis through Noninvasive Tests in Steatotic Liver Disease
by: Yuri Cho
Published: (2024-11-01)

The multifaceted roles of B lymphocytes in metabolic dysfunction–associated steatotic liver disease
by: Huige Li, et al.
Published: (2024-09-01)

Treatment of HCV infection in patients with steatotic liver disease
by: Robert Flisiak, et al.
Published: (2024-07-01)

Helicobacter pylori infection in the pathophysiology of metabolic dysfunction-associated steatotic liver disease and its complications
by: Jannis Kountouras, et al.
Published: (2025-03-01)

MASLD-related HCC: Multicenter study comparing patients with and without cirrhosis
by: Carole Vitellius, et al.
Published: (2024-10-01)

METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE: UPDATE
by: Maria Gabriela Fernandes DEZAN, et al.
Published: (2025-09-01)

Advances in the Pathogenesis of Metabolic Liver Disease-Related Hepatocellular Carcinoma
by: Chen P, et al.
Published: (2024-03-01)

Prevalence of steatotic liver disease and associated fibrosis in the general population: An epidemiological survey: Letter to the editor on “Epidemiology of metabolic dysfunction-associated steatotic liver disease”
by: Lin Guan, et al.
Published: (2025-04-01)

Steatotic Liver Disease: New Nomenclature and Its Localization in the Russian Federation
by: K. L. Raikhelson, et al.
Published: (2024-05-01)

A high reticulocyte count is a risk factor for the onset of metabolic dysfunction-associated steatotic liver disease: Cross-sectional and prospective studies of data of 310,091 individuals from the UK Biobank
by: Peng-Cheng Ma, et al.
Published: (2024-07-01)

Genome-Wide DNA Methylation Markers Associated With Metabolic Liver Cancer
by: Samuel O. Antwi, et al.
Published: (2025-01-01)

Prognosis of biopsy-confirmed metabolic dysfunction-associated steatotic liver disease: A sub-analysis of the CLIONE study
by: Michihiro Iwaki, et al.
Published: (2024-04-01)

Lipidome Changes Associated with a Diet-Induced Reduction in Hepatic Fat among Adolescent Boys with Metabolic Dysfunction-Associated Steatotic Liver Disease
by: Helaina E. Huneault, et al.
Published: (2024-03-01)

A social media listening study of patients’ experiences relating to metabolic dysfunction-associated steatotic liver disease: The LISTEN-MASLD study
by: Jeffrey V. Lazarus, et al.
Published: (2025-01-01)

Serum metabolites characterize hepatic phenotypes and reveal shared pathways: results from population-based imaging
by: Juliane Maushagen, et al.
Published: (2025-07-01)

Identification the shared pathogenesis between chronic hepatitis B and non-alcoholic fatty liver disease: Evidence from transcriptome data
by: Yan Yang, et al.
Published: (2023-10-01)

The Role of Neuregulin-1 in Steatotic and Non-Steatotic Liver Transplantation from Brain-Dead Donors
by: Marc Micó-Carnero, et al.
Published: (2022-04-01)

First Evidence of Anti-Steatotic Action of Macrotympanain A1, an Amphibian Skin Peptide from <i>Odorrana macrotympana</i>
by: Ilaria Demori, et al.
Published: (2022-11-01)

Applicability of Statins in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
by: Thaninee Prasoppokakorn
Published: (2025-01-01)

From adiposity to steatosis: metabolic dysfunction-associated steatotic liver disease, a hepatic expression of metabolic syndrome – current insights and future directions
by: Bruno Basil, et al.
Published: (2024-12-01)

Identifying metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes mellitus using clinic-based prediction tools
by: Juma Alkaabi, et al.
Published: (2024-09-01)

Circulating angiopoietin-like protein 8 (ANGPTL8) and steatotic liver disease related to metabolic dysfunction: an updated systematic review and meta-analysis
by: Farah Abdelhameed, et al.
Published: (2025-04-01)

Risk of Hepatocellular Carcinoma by Steatotic Liver Disease and Its Newly Proposed Subclassification
by: Byeong Geun Song, et al.
Published: (2024-03-01)

Examining the prevalence of hepatic steatosis and advanced fibrosis using non-invasive measures across Canada: A national estimate using the Canadian Health Measures Survey (CHMS) from 2009-2019
by: Jacob Romano, et al.
Published: (2025-01-01)

Characteristics and long-term mortality of individuals with MASLD, MetALD, and ALD, and the utility of SAFE score
by: Pimsiri Sripongpun, et al.
Published: (2024-10-01)

Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity
by: Gi-Ae Kim, et al.
Published: (2023-10-01)

From Dysbiosis to Hepatic Inflammation: A Narrative Review on the Diet-Microbiota-Liver Axis in Steatotic Liver Disease
by: Andrea Pasta, et al.
Published: (2025-01-01)

Consecutive fecal microbiota transplantation for metabolic dysfunction-associated steatotic liver disease: a randomized controlled trial
by: Bas Groenewegen, et al.
Published: (2025-12-01)

Effectiveness and active ingredients of digital behaviour change interventions for MASLD: A systematic review and meta-analysis
by: Hollie Smith, et al.
Published: (2025-10-01)